Compositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression
US-12098399-B2 · Sep 24, 2024 · US
Activin-actriia antagonists and uses for treating multiple myeloma
US2017190784A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017190784-A1 |
| Application number | US-201715403987-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 11, 2017 |
| Priority date | Nov 23, 2005 |
| Publication date | Jul 6, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
First claim
Opening claim text (preview).
1 - 65 . (canceled) 66 . A method for treating or preventing multiple myeloma in a human patient, the method comprising administering to the patient an effective amount of an anti-activin antibody or fragment thereof. 67 . The method of claim 66 , wherein the antibody or fragment thereof is a chimeric antibody. 68 . The method of claim 66 , wherein the antibody or fragment thereof is a humanized antibody. 69 . The method of claim 66 , wherein the antibody or fragment thereof is a human antibody. 70 . The method of claim 66 , wherein the antibody or fragment thereof is a monoclonal antibody. 71 . The method of claim 66 , wherein the antibody or fragment thereof is an F(ab) 2 fragment. 72 . The method of claim 66 , wherein the antibody or fragment thereof is an Fab fragment. 73 . The method of claim 66 , wherein the antibody or fragment thereof is a single chain antibody. 74 . The method of claim 66 , wherein the antibody or fragment thereof is a bi-specific antibody. 75 . The method of claim 66 , wherein the antibody or fragment thereof further comprises one or more agents selected from: a radioisotope, a fluorescent compound, and an enzyme or enzyme co-factor. 76 . The method of claim 66 , wherein the antibody or fragment thereof binds to activin A. 77 . The method of claim 66 , wherein the antibody or fragment thereof binds to activin B. 78 . The method of claim 66 , wherein the antibody or fragment thereof binds to activin A and B. 79 . The method of claim 66 , wherein the antibody or fragment thereof inhibits activin from binding to ActRIIa. 80 . The method of claim 66 , wherein the antibody or fragment thereof reduces tumor burden in the patient. 81 . The method of claim 66 , wherein the antibody or fragment thereof treats or prevents bone loss in the patient. 82 . The method of claim 66 , wherein the antibody or fragment thereof is administered to the patient in combination with one or more bone-active agents selected from: a calcium supplement, vitamin D, a bisphosphonate, calcitonin, estrogen, parathyroid hormone, and raloxifene.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017190784A1 cover?
- In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
- Who is the assignee on this patent?
- Acceleron Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/4702. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).